Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “TREAT”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 145 records · Page 8

Uncertainty and Sensitivity Analysis of TREAT Transient Test #15

The U.S. Department of Energy (DOE) is preparing for the resumption of transient testing using the Transient Reactor Test Facility (TREAT) located at the Idaho National Laboratory (INL). In order to support the analysis of TREAT operation and experiment planning, the MAMMOTH reactor physics team has recently begun development of uncertainty and sensitivity analysis for the TREAT core simulated via MAMMOTH. MAMMOTH is a high-fidelity three-dimensional transient multi-physics code developed at INL under the DOE-NE Advanced Modeling and Simulation program (NEAMS) [1]. This research is part of the development presenting some initial uncertainty and sensitivity analysis of TREAT Transient Test #15 [2]. In this summary, we employ the Sobol sampling strategy implemented in RAVEN [3] to efficiently perform the sensitivity and uncertainty analysis. The idea is using Sobol functional decomposition with generalized polynomial chaos (gPC) expansions to estimate the responses of interest [4]. The gPC coefficients are then computed via the spectral projection method with sparse grid approach. In addition, this strategy includes evaluation of the second or higher order sensitivity indices, allowing the study of interactions between several input variables. The principal focus of this analysis is to quantify the uncertainties in the total power and maximum fuel temperatures with respect to uncertainties in the initial transient conditions, such as rated power, fuel temperature, graphite fuel density and control rod boron concentration. In addition, both the first order and second order time-dependent sensitivity indices are computed and analyzed. The results show that the interactions between initial control rod boron concentration and the rated power will contribute at most 1% to the total uncertainty of the power peak.

22 GENERAL STUDIES OF NUCLEAR REACTORS↗

ARCS Replacement at TREAT for TRTR 2020 - Abstract

The Transient REActor Test (TREAT) facility was restarted in 2017 to perform reactor fuels testing under transient conditions, following shutdown in 1994 and 23 years in non-operational standby. TREAT is a transient reactor that, like most pulsing reactors, can create natural shaped power pulses. However, TREAT provides the ability to shape the power pulse and control the energy deposition rate on the test specimens by automatically controlling the amount of reactivity insertion over time. The original automatic reactor control system (ARCS) was created in the 1980s using INTEL 8086 CPU boards and software written in assembly code. The need to maintain the system for the next 40+ years of TREAT life led to the decision to replace ARCS with modern hardware while maintaining the original functionality. After a prototyping effort, the replacement was successfully completed in the first quarter of 2020. The process and results of that effort are reported here.

21 SPECIFIC NUCLEAR REACTORS AND ASSOCIATED PLANTS↗

Thermal-hydraulic and Fuel Performance Scoping Studies of a Flowing Water Capsule in TREAT

The restart of the Transient Reactor Test (TREAT) facility has provided a much needed capability for integral transient testing of nuclear fuel. This testing is necessary to qualify new fuel concepts such as those developed under the Accident Tolerant Fuel (ATF) program, increasing the burnup limit of light water reactor (LWR) fuels, or a variety of other programs under the Advanced Fuels Campaign (AFC). The ATF campaign has been the main driver behind the development and implementation of a variety of capsules for TREAT experiments. The Separate-Effect Test Holder (SETH) was a dry capsule that enabled testing of ATF concepts under reactivity-initiated accident (RIA) heating conditions. Following SETH, the Static Environment Rodlet Transient Test Apparatus (SERTTA) was developed to enable RIA testing in a static water environment. In efforts to support the need for future Loss-of-Coolant Accident (LOCA) tests, the Transient Water Irradiation System for TREAT (TWIST) capsule has been developed that allows for water to drain from around the fuel rod and lower the pressure to simulate LOCA conditions. All these capsules that have been developed for LWR fuel testing all lack the capability for forced convective cooling which in some applications may limit their ability to test under prototypic conditions. A design and modeling effort has been started to modify the TWIST capsule by adding a flow tube and impeller that can create flowing coolant conditions for the fuel rod. RELAP5-3D and BISON models are being used to study the differences between RIA, LOCA, Anticipated Operational Occurrences (AOO), LWR power cycling, and other transient scenarios under flowing conditions capable in the flowing capsule and the current stagnant water capsules (SERTTA and TWIST). The scoping study will provide guidance on the needed capabilities for the flowing capsule and the limitations of the currently developed capsule for LWR testing in TREAT.

11 NUCLEAR FUEL CYCLE AND FUEL MATERIALS↗

TREAT neutronics analysis and design support, Part II: Multi-SERTTA-CAL

Experiment vehicle design is necessary in preparation for Transient Reactor Test (TREAT) facility restart and the resumption of transient testing to support Accident Tolerant Fuel (ATF) characterization and other future fuels testing requirements. Currently the most mature vehicle design is the Multi-SERTTA (Static Environments Rodlet Transient Test Apparatuses), which can accommodate up to four concurrent rodlet-sized specimens under separate environmental conditions. Robust test vehicle design requires neutronics analyses to support design development, optimization of the power coupling factor (PCF) to efficiently maximize energy generation in the test fuel rodlets, and experiment safety analyses. An integral aspect of prior TREAT transient testing was the incorporation of calibration experiments to experimentally evaluate and validate test conditions in preparation of the actual fuel testing. The calibration experiment package established the test parameter conditions to support fine-tuning of the computational models to deliver the required energy deposition to the fuel samples. The calibration vehicle was designed to be as near neutronically equivalent to the experiment vehicle as possible to minimize errors between the calibration and final tests. The Multi-SERTTA-CAL vehicle was designed to serve as the calibration vehicle supporting Multi-SERTTA experimentation. Models of the Multi-SERTTA-CAL vehicle containing typical PWR-fuel rodlets were prepared and neutronics calculations were performed using MCNP6.1 with ENDF/B-VII.1 nuclear data libraries; these results were then compared against those performed for Multi-SERTTA to determine the similarity and possible design modification necessary prior to construction of these experiment vehicles. The estimated reactivity insertion worth into the TREAT core is very similar between the two vehicle designs, with the primary physical difference being a hollow Inconel tube running down the length of the calibration vehicle. Calculations of PCF indicate that on average there is a reduction of approximately 6 % for PWR fuel rodlets irradiated under both wet and dry conditions. Changes to the primary or secondary vessel structure in the calibration vehicle can be performed to offset this discrepancy and maintain neutronic equivalency. Current possible modifications to the calibration vehicle include reduction of the primary vessel wall thickness, swapping Zircaloy-4 for stainless steel 316 in the secondary containment, or slight modification to the temperature and pressure of the water environment within the primary vessel. Removal of some of the instrumentation within the calibration vehicle can also serve to slightly increase the PCF. Future efforts include further modification and optimization of the Multi-SERTTA and Multi-SERTTA-CAL designs in preparation of actual TREAT transient testing. Experimental results from both test vehicles will be compared against calculational results and methods to provide validation and support additional neutronics analyses. (authors)

11 NUCLEAR FUEL CYCLE AND FUEL MATERIALS↗

Thermal-hydraulic performance of the TREAT Multi-SERTTA for reactivity initiated accident experiments

Experimental testing in the Multi-Static Environment Rodlet Transient Test Apparatus (SERTTA) will lead the rebirth of transient fuel testing in the United States as part of the Accident Tolerant Fuels (ATF) program. The Multi-SERTTA is comprised of 4 isolated pressurized environments capable of a wide variety of working fluids and thermal conditions. Ultimately, the TREAT reactor as well as the Multi-SERTTA test vehicle serve the purpose of providing desired thermal-hydraulic boundary conditions to the test specimen. The initial ATF testing in TREAT will focus on reactivity insertion accident (RIA) events using both gas and water environments including typical PWR operating pressures and temperatures. The heat transfer conditions during the high energy power pulses of RIA events remains a subject of large uncertainty and great importance for fuel performance predictions. To support transient experiments, the Multi-SERTTA vehicle has been modeled using RELAP5 with a baseline test specimen composed of fresh UO{sub 2} fuel in zircaloy cladding. The results show that for energy depositions less than 1380 J/g-UO{sub 2}, the vessel environment remains sub-supercritical. Two extremes of gap conductance show significant effect on event timing and peak cladding temperature but little effect on end state conditions. Inclusion of oxidation has increasing impact for increasing energy depositions. The effect of oxidation is non-negligible for planned TREAT experiments in the range of explored energy depositions. Pulse width has little impact on thermal hydraulic conditions under the assumptions used in this analysis. The model used in this work has been coupled to the fuel performance code, BISON, to accomplish best estimate predictive capability for Multi-SERTTA experiments. The results show the great flexibility and capacity of the TREAT Multi-SERTTA test vehicle to provide testing under a wide range of prototypic thermal-hydraulic conditions as never done before.

11 NUCLEAR FUEL CYCLE AND FUEL MATERIALS↗

TREAT reactor LEU fuel-clad chemical interaction empirical modeling analysis

DOE is converting TREAT (Transient Reactor Test) facility from its existing highly enriched uranium (HEU) core to a low-enriched uranium (LEU) core. In order to assess the magnitude of chemical interaction between fuel and cladding materials during physical contact under expected TREAT operational limits, planned transients tests, and reactivity accident scenarios, a combination of experimental testing and thermodynamic modeling was performed to predict the expected chemical interactions among fuel and cladding chemical constituents. Thermodynamic calculations were then validated with empirical data from experiments that emulate TREAT's expected upper operational limits. Pellet samples composed of LEU oxide powder dispersed in a graphite matrix had intimate contact with zirconium-based alloy cladding. The samples were subjected to long-term isothermal heating under high vacuum. Specimen characterization consisted of scanning electron microscopy, x-ray diffraction analysis, and x-ray tomography. ThermoCalc software and Ellingham's diagrams were used for thermodynamic calculations. The X-ray tomography and SEM analysis of the pellets showed a homogeneous distribution of UO{sub 2} particles within the graphite matrix with isolated larger UO{sub 2} agglomerates. The SEM analysis showed the formation of a lamellar structure between the large UO{sub 2} agglomerate and the graphite matrix. This is an indication that diffusion is taking place at a rather moderate temperature and reaction time during the pellet fabrication. Secondary phases, with high Al and Mg content, were detected inside a UO{sub 2} agglomerate using SEM in SE/EBSD mode and chemical analysis with EDS. LEU feedstock impurities, as Al and Mg, seem to promote the chemical reactivity between UO{sub 2} particles and graphite matrix. XRD analysis of a pellet sample showed the presence of UO{sub 2} and graphite, but no other crystalline phases were detected with this technique. Thermodynamic analysis through the use of Ellingham diagrams showed that within TREAT's operational to reactivity accident temperature (278-820 Celsius degrees), UO{sub 2} can be reduced to U metal by Zr due to a more favorable ΔG for the oxidation of Zr.

11 NUCLEAR FUEL CYCLE AND FUEL MATERIALS↗

TREAT Transient Test Reactor Restart Status

Transient testing involves placing nuclear fuel or material into the core of a nuclear reactor designed to operate at high power for a short time, and subjecting the nuclear fuel or material to short bursts of intense, high power radiation. After the experiment is completed, the fuel or material is analyzed to determine the effects of the radiation. The results are then used in fuel or material design and/or qualification. Transient testing is required for essentially all nuclear fuel design and qualification efforts to learn how nuclear fuel will respond during accidents involving transient overpower and/or under cooling events. For example, nuclear fuel may fragment when exposed to higher than normal power. This fragmentation can cause unacceptable performance. Transient testing is also needed to validate performance models for nuclear fuel and materials. These models, when validated, will dramatically shorten the development and qualification life cycle for nuclear fuels, supporting rapid development of low emissions, reliable power generation. In the past, transient testing was primarily done in facilities that no longer exist. The U.S. Department of Energy evaluated how to provide the required transient testing capability and, following completion of the National Environmental Policy Act process, they selected the Transient Reactor Test (TREAT) facility to resume transient testing. TREAT is located at Idaho National Laboratory (INL). The TREAT reactor was used from 1959 to 1994 to conduct more than 2,500 nuclear fuel transient tests, and was placed in standby in 1994. TREAT is capable of transients in excess of 19 GW. The paper describes the progress towards restart. The restart efforts have revealed that the plant fuel and equipment is acceptable for future operations. The safety basis development, procedures, and training are well under way. Experiment capability preparations are in progress. Reactor startup is anticipated no later than 2018. (author)

11 NUCLEAR FUEL CYCLE AND FUEL MATERIALS↗

Uncertainty and Sensitivity Analysis of TREAT Transient Test no. 15

The U.S. Department of Energy (DOE) is preparing for the resumption of transient testing using the Transient Reactor Test Facility (TREAT) located at the Idaho National Laboratory (INL). In order to support the analysis of TREAT operation and experiment planning, the MAMMOTH reactor physics team has recently begun development of uncertainty and sensitivity analysis for the TREAT core simulated via MAMMOTH. MAMMOTH is a high-fidelity three-dimensional transient multi-physics code developed at INL under the DOE-NE Advanced Modeling and Simulation program (NEAMS). This research is part of the development presenting some initial uncertainty and sensitivity analysis of TREAT Transient Test no. 15. In this summary, we employ the Sobol sampling strategy implemented in RAVEN to efficiently perform the sensitivity and uncertainty analysis. The idea is using Sobol functional decomposition with generalized polynomial chaos (gPC) expansions to estimate the responses of interest. The gPC coefficients are then computed via the sparse grid spectral projection method. In addition, this strategy includes evaluation of the second or higher order sensitivity indices, allowing the study of interactions between several input variables. The principal focus of this analysis is to quantify the uncertainties in the total power and maximum fuel temperatures with respect to uncertainties in the initial transient conditions, such as rated power, fuel temperature, graphite fuel density and control rod boron concentration. In addition, both the first order and second order time-dependent sensitivity indices are computed and analyzed. The results show that the interactions between initial control rod boron concentration and the rated power will contribute at most 1% to the total uncertainty of the power peak.

21 SPECIFIC NUCLEAR REACTORS AND ASSOCIATED PLANTS↗

Development of the TREAT M2 experiment as a transient benchmark

A transient benchmark based on the Transient Reactor Test Facility (TREAT) M2 Calibration experiment (M2-CAL) is under development. TREAT, at Idaho National Laboratory, is a graphite moderated air-cooled research reactor which has been used extensively for fuel material testing under extreme and accident conditions. Accurate benchmark models are a beneficial component in the operations, experimental planning, and development of TREAT. In this work, we present a transient benchmark model for the M2-CAL experiment core loading. The benchmark model incorporates the coupling between the Monte Carlo Code SERPENT and the computational fluid dynamics code OpenFOAM to capture the temperature feedback mechanism. The M2-CAL transient 2580 was simulated in this work. A pre-transient analysis was performed to determine the optimum core composition and conditions before the beginning of the transient. The analysis was validated against historic TREAT kinetic measurements and the worth of the transient rod T-2. The axial power distribution in the flux wire for the M2-CAL experiment was determined and contrasted with the experiment. The model was then used to simulate the M2-CAL transient 2580 experiment based on the reported pre-transient and transient conditions. Several transient observables were calculated and compared to the experiment. The model shows good agreement with the experimental power traces, period, and average increase of power at the power ramp (time > 7.8 s). Inverse point kinetics analysis was performed during the period of the power ramp for the model and the experiment based on that, the temperature feedback component was isolated and contrasted with the experimental feedback. (authors)

21 SPECIFIC NUCLEAR REACTORS AND ASSOCIATED PLANTS↗

Performance Analysis and Simulaion of the Hydraulic Scram System in TREAT Reactor

The Transient Reactor Test Facility (TREAT) at Idaho National Laboratory (INL) serves a vital role in nuclear fuel safety research, enabling transient experiments that simulate reactivity excursions and accident scenarios. Central to these operations is the transient control rod drive system (TCRDS), which drives rapid motion of the transient control rods such that TREAT can simulate rapid power changes typical of reactor accidents. The reliability and performance of this system are critical for protecting both fuel specimens and reactor infrastructure. This study presents the initial phase of a two-year investigation into the dynamics and reliability of the TREAT hydraulic TCRDS. Conducted in collaboration with INL, the research employs a combined computational and experimental approach to analyze the system's response time, pressure transients, and potential failure modes. Emphasis is placed on understanding how fluid characteristics influence the TCRDS’s ability to achieve both rapid power changes and mechanical stability. The TRDS and the skid that powers it will be analyzed throughout this investigation. Computational modeling using computational fluid dynamics (CFD) will simulate the hydraulic response under varying conditions. In parallel, experimental testing planned at INL will validate these models and capture key performance metrics. This paper outlines the system design, analytical framework, and modeling strategies that form the foundation for later testing. Ultimately, this work aims to support improvements to the TCRDS’s design and reliability, contributing to the broader goal of enhancing nuclear fuel safety and sustaining TREAT’s mission as a premier nuclear fuel test facility.

21 - SPECIFIC NUCLEAR REACTORS AND ASSOCIATED PLAN↗

Countermeasures for Preventing and Treating Opioid Overdose

The only medication available currently to prevent and treat opioid overdose (naloxone) was approved by the US Food and Drug Administration (FDA) nearly 50 years ago. Due to its pharmacokinetic and pharmacodynamic properties, naloxone has limited utility under some conditions and would not be effective to counteract mass casualties involving large-scale deployment of weaponized synthetic opioids. To address shortcomings of current medical countermeasures for opioid toxicity, a trans-agency scientific meeting was convened by the US National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH) on August 6 and 7, 2019, to explore emerging alternative approaches for treating opioid overdose in the event of weaponization of synthetic opioids. The meeting was initiated by the Chemical Countermeasures Research Program (CCRP), was organized by NIAID, and was a collaboration with the National Institute on Drug Abuse/NIH (NIDA/NIH), the FDA, the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA). This paper provides an overview of several presentations at that meeting that discussed emerging new approaches for treating opioid overdose, including the following: (1) intranasal nalmefene, a competitive, reversible opioid receptor antagonist with a longer duration of action than naloxone; (2) methocinnamox, a novel opioid receptor antagonist; (3) covalent naloxone nanoparticles; (4) serotonin (5-HT)1A receptor agonists; (5) fentanyl-binding cyclodextrin scaffolds; (6) detoxifying biomimetic “nanosponge” decoy receptors; and (7) antibody-based strategies. These approaches could also be applied to treat opioid use disorder.

59 BASIC BIOLOGICAL SCIENCES↗

Retrospective evaluation of dosimetric quality for prostate carcinomas treated with 3D conformal, intensity modulated and volumetric modulated arc radiotherapy

This study examines and compares the dosimetric quality of radiotherapy treatment plans for prostate carcinoma across a cohort of 163 patients treated across five centres: 83 treated with three-dimensional conformal radiotherapy (3DCRT), 33 treated with intensity modulated radiotherapy (IMRT) and 47 treated with volumetric modulated arc therapy (VMAT). Treatment plan quality was evaluated in terms of target dose homogeneity and organs at risk (OAR), through the use of a set of dose metrics. These included the mean, maximum and minimum doses; the homogeneity and conformity indices for the target volumes; and a selection of dose coverage values that were relevant to each OAR. Statistical significance was evaluated using two-tailed Welch's T-tests. The Monte Carlo DICOM ToolKit software was adapted to permit the evaluation of dose metrics from DICOM data exported from a commercial radiotherapy treatment planning system. The 3DCRT treatment plans offered greater planning target volume dose homogeneity than the other two treatment modalities. The IMRT and VMAT plans offered greater dose reduction in the OAR: with increased compliance with recommended OAR dose constraints, compared to conventional 3DCRT treatments. When compared to each other, IMRT and VMAT did not provide significantly different treatment plan quality for like-sized tumour volumes. This study indicates that IMRT and VMAT have provided similar dosimetric quality, which is superior to the dosimetric quality achieved with 3DCRT.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Piriformis Syndrome: Long-Term Follow-up in Patients Treated with Percutaneous Injection of Anesthetic and Corticosteroid Under CT Guidance

Purpose: This study was designed to evaluate the efficacy of CT-guided injection of anesthetic and corticosteroid for the treatment of pain in patients with piriformis syndrome unresponsive to conservative treatment. Methods: We enrolled 23 patients with piriformis syndrome, proposing a percutaneous intramuscular injection of methylprednisone-lidocaine. Among them, 13 patients accepted and 10 refused to undergo the procedure; the second group was used as a control group. Clinical evaluation was performed with four maneuvers (Lasegue sign, FAIR test, Beatty and Freiberg maneuver) and a VAS questionnaire before the injection, after 5-7 days, and after 2 months. A telephonic follow-up was conducted to 3, 6, and 12 months. Results: Procedural success was achieved in all patients who were treated without any complications. After 2 months, among 13 treated subjects, 2 of 13 patients showed positivity to FAIR test (hip flexion, adduction, and internal rotation), 2 of 13 were positive to Lasegue sign, and the Beatty maneuver was positive in 1 patient. Patients who underwent conservative treatment were positive respectively in 7 of 10 (p = 0.01), 6 of 10 (p = 0.03), and 6 of 10 (p = 0.01). The VAS score showed a difference between patients treated with percutaneous approach and those managed with conservative therapy at the baseline evaluation (p = 0.04), after 2 months (p = 0.02), and 12 months (p = 0.002). We observed a significant reduction in pain for patients treated percutaneously, who were evaluated with the VAS scale at 5-7 days, 2 months, 3, 6, and 12 months (p < 0.001). Conclusions: Our findings suggested potential benefit from the percutaneous injection of anesthetics and corticosteroids under CT guidance for the treatment of piriformis syndrome.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Comparison of Survival Rate in Primary Non-Small-Cell Lung Cancer Among Elderly Patients Treated With Radiofrequency Ablation, Surgery, or Chemotherapy

Purpose: We retrospectively compared the survival rate in patients with non-small-cell lung cancer (NSCLC) treated with radiofrequency ablation (RFA), surgery, or chemotherapy according to lung cancer staging. Materials and Methods: From 2000 to 2004, 77 NSCLC patients, all of whom had WHO performance status 0-2 and were >60 years old, were enrolled in a cancer registry and retrospectively evaluated. RFA was performed on patients who had medical contraindications to surgery/unsuitability for surgery, such as advanced lung cancer or refusal of surgery. In the RFA group, 40 patients with inoperable NSCLC underwent RFA under computed tomography (CT) guidance. These included 16 patients with stage I to II cancer and 24 patients with stage III to IV cancer who underwent RFA in an adjuvant setting. In the comparison group (n = 37), 13 patients with stage I to II cancer underwent surgery; 18 patients with stage III to IV cancer underwent chemotherapy; and 6 patients with stage III to IV cancer were not actively treated. The survival curves for RFA, surgery, and chemotherapy in these patients were calculated using Kaplan-Meier method. Results: Median survival times for patients treated with (1) surgery alone and (2) RFA alone for stage I to II lung cancer were 33.8 and 28.2 months, respectively (P = 0.426). Median survival times for patients treated with (1) chemotherapy alone and (2) RFA with chemotherapy for stage III to IV cancer were 29 and 42 months, respectively (P = 0.03). Conclusion: RFA can be used as an alternative treatment to surgery for older NSCLC patients with stage I to II inoperable cancer and can play a role as adjuvant therapy with chemotherapy for patients with stage III to IV lung cancer.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Intrahepatic Flow Redistribution in Patients Treated with Radioembolization

IntroductionIn planning Yttrium-90 ({sup 90}Y)-radioembolizations, strategy problems arise in tumours with multiple arterial supplies. We aim to demonstrate that tumours can be treated via one main feeding artery achieving flow redistribution by embolizing accessory vessels.MethodsOne hundred {sup 90}Y-radioembolizations were performed on 90 patients using glass microspheres. In 19 lesions/17 patients, accessory branches were found feeding a minor tumour portion and embolized. In all 17 patients, the assessment of the complete perfusion was obtained by angiography and single photon emission computerized tomography–computerized tomography (SPECT–CT). Dosimetry, toxicity, and tumor response rate of the patients treated after flow redistribution were compared with the 83 standard-treated patients. Seventeen lesions in 15 patients with flow redistribution were chosen as target lesions and evaluated according to mRECIST criteria.ResultsIn all patients, the complete tumor perfusion was assessed immediately before radioembolization by angiography in all patients and after the {sup 90}Y-infusion by SPECT–CT in 15 of 17 patients. In the 15 assessable patients, the response rate in their 17 lesions was 3 CR, 8 PR, and 6 SD. Dosimetric and toxicity data, as well tumour response rate, were comparable with the 83 patients with regular vasculature.ConclusionsAll embolization procedures were performed successfully with no complications, and the flow redistribution was obtained in all cases. Results in term of toxicity, median dose administered, and radiological response were comparable with standard radioembolizations. Our findings confirmed the intratumoral flow redistribution after embolizing the accessory arteries, which makes it possible to treat the tumour through its single main feeding artery.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Investigation of the Microstructural Changes and Hardness Variations of Sub-Zero Treated Cr-V Ledeburitic Tool Steel Due to the Tempering Treatment

The microstructure and tempering response of Cr-V ledeburitic steel Vanadis 6 subjected to sub-zero treatment at − 196 °C for 4 h have been examined with reference to the same steel after conventional heat treatment. The obtained experimental results infer that sub-zero treatment significantly reduces the retained austenite amount, makes an overall refinement of microstructure, and induces a significant increase in the number and population density of small globular carbides with a size 100-500 nm. At low tempering temperatures, the transient M{sub 3}C-carbides precipitated, whereas their number was enhanced by sub-zero treatment. The presence of chromium-based M{sub 7}C{sub 3} precipitates was evidenced after tempering at the temperature of normal secondary hardening; this phase was detected along with the M{sub 3}C. Tempering above 470 °C converts almost all the retained austenite in conventionally quenched specimens while the transformation of retained austenite is rather accelerated in sub-zero treated material. As a result of tempering, a decrease in the population density of small globular carbides was recorded; however, the number of these particles retained much higher in sub-zero treated steel. Elevated hardness of sub-zero treated steel can be referred to more completed martensitic transformation and enhanced number of small globular carbides; this state is retained up to a tempering temperature of around 500 °C in certain extent. Correspondingly, lower as-tempered hardness of sub-zero treated steel tempered above 500 °C is referred to much lower contribution of the transformation of retained austenite, and to an expectedly lower amount of precipitated alloy carbides.

36 MATERIALS SCIENCE↗

2-Methoxy-4-vinylphenol can induce cell cycle arrest by blocking the hyper-phosphorylation of retinoblastoma protein in benzo[a]pyrene-treated NIH3T3 cells

Research highlights: {yields} 2M4VP activated the expression of p21 and p15 protein, and down-regulated the expression of cyclin D1 and cyclin E. {yields} 2M4VP inhibited hyper-phosphorylation of Rb protein. {yields} 2M4VP induced cell cycle arrest from G1 to S. {yields} 2M4VP inhibited hyper-proliferation of the cells in BaP-treated cells. {yields} 2M4VP induces growth arrest of BaP-treated cells by blocking hyper-phosphorylation of Rb via regulating the expression of cell cycle-related proteins. -- Abstract: Benzo[a]pyrene (BaP) is an environment carcinogen that can enhance cell proliferation by disturbing the signal transduction pathways in cell cycle regulation. In this study, the effects of 2M4VP on cell proliferation, cell cycle and cell cycle regulatory proteins were studied in BaP-treated NIH 3T3 cells to establish the molecular mechanisms of 2M4VP as anti-proliferative agents. 2M4VP exerted a dose-dependent inhibitory effect on cell growth correlated with a G1 arrest. Analysis of G1 cell cycle regulators expression revealed 2M4VP increased expression of CDK inhibitor, p21Waf1/Cip1 and p15 INK4b, decreased expression of cyclin D1 and cyclin E, and inhibited kinase activities of CDK4 and CDK2. However, 2M4VP did not affect the expression of CDK4 and CDK2. Also, 2M4VP inhibited the hyper-phosphorylation of Rb induced by BaP. Our results suggest that 2M4VP induce growth arrest of BaP-treated NIH 3T3 cells by blocking the hyper-phosphorylation of Rb via regulating the expression of cell cycle-related proteins.

60 APPLIED LIFE SCIENCES↗

Differences in Patterns of Failure in Patients Treated With Accelerated Partial Breast Irradiation Versus Whole-Breast Irradiation: A Matched-Pair Analysis With 10-Year Follow-Up

Purpose: To examine 10-year results of a single institution's experience with radiotherapy limited to the region of the tumor bed (i.e., accelerated partial breast irradiation, [APBI]) in selected patients treated with breast-conserving therapy (BCT) and compare them with results of matched BCT patients who underwent whole-breast irradiation (WBI). Patients and Methods: A total of 199 patients with early-stage breast cancer were treated prospectively with BCT and APBI using interstitial brachytherapy. To compare potential differences in local recurrence rates on the basis of the volume of breast tissue irradiated, patients in the APBI group were matched with 199 patients treated with WBI. Match criteria included tumor size, nodal status, age at diagnosis, margins of excision, estrogen receptor status, and use of adjuvant tamoxifen therapy. Local-regional control, disease-free survival, and overall survival were analyzed between treatment groups. Results: Median follow-up for surviving patients was 9.6 years (range, 0.3-13.6 years). Eight ipsilateral breast tumor recurrences (IBTRs) were observed in patients treated with APBI. The cumulative incidence of IBTR at 10 years was 5%. On matched-pair analysis, the rate of IBTR was not statistically significantly different between the patient groups (4%, 95% confidence interval [CI] 1.3-6.7% for WBI therapy patients vs. 5%, 95% CI 1.5-8.5% for APBI patients; p = 0.48). Conclusions: Radiation therapy limited to the region of the tumor bed (APBI) produced 10-year local control rates comparable to those from WBI in selected low-risk patients.

62 RADIOLOGY AND NUCLEAR MEDICINE↗